Press Releases

Press Releases

Date Title
04/16/19 Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b
04/12/19 Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection,
04/09/19 Vaxart Announces Pricing of Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 9, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public
03/28/19 Vaxart to Present at Global Medical Meetings in April
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in
03/27/19 Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 27, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the
03/20/19 Vaxart Announces Closing of Registered Direct Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 20, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of
03/19/19 Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive
03/19/19 Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
- First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18 - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by
02/06/19 Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial